becton dickinson bdx delivers solid 095430655

Becton Dickinson's Q2 results show mixed performance: strong growth in biologic drug delivery and monitoring offset by headwinds in Alaris and vaccine segments. The voluntary product hold on ChloraPrep/PurPrep (FDA warning letter) creates a temporary supply disruption for those antiseptic products in the U.S., but no patient safety concerns. Overall, the impact is company-specific, with no major sector-wide scarcity or price signal. The revenue beat and maintained guidance suggest stable margins, but the product hold may pressure near-term U.S. sales.